Dabrafenib was also a selective inhibitor of BRAF kinase for patients suffering from BRAF-mutated melanoma, advanced non-small cell lung cancer, and anaplastic thyroid cancer harboring the BRAFV600E mutation (Puszkiel et al., 2019). Here, BRAF is linked to non-small cell lung carcinoma.